Ultromics Raises $33M in Series B Funding to Help Transform Cardiac Disease Treatment
Summary
OXFORD, England, Aug. 16, 2021 /PRNewswire/ -- Ultromics, a leader in AI enabled cardiovascular imaging solutions, announced today that it has raised $33 million in a Series B funding round. "Cardiovascular disease is the leading cause of morbidity and mortality in the United States, and Ultromics offers groundbreaking AI solutions for more accurate diagnosis," said Dr. Emir Sandhu, Managing Director at the Blue Venture Fund. "Ultromics software significantly improves the ability of clinicians to leverage low-cost ultrasound imaging to address cardiovascular disease, one of the greatest healthcare burdens of our generation" said Dr. Vijay Barathan, Optum Ventures. Born at the University of Oxford and built-in partnership with the U.K.s NHS, Ultromics has developed the first fully automated solution for echocardiography and analysis of global longitudinal strain (GLS). Ultromics delivers analysis to any vendor within minutes, with zero variability, without any disruption to workflow, and can even predict a patients risk of developing coronary artery disease (CAD).